Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 402 Colorectal Neoplasms 317 Rectal Neoplasms 235 Stomach Neoplasms 209 Pancreatic Neoplasms 137 Neoplasm Metastasis 123 Colonic Neoplasms 94 Neoplasms 86 Triple Negative Breast Neoplasms 64 Esophageal Neoplasms 57 Biliary Tract Neoplasms 39 Nasopharyngeal Carcinoma 37 Cholangiocarcinoma 31 Adenocarcinoma 31 Carcinoma, Hepatocellular 30 Gallbladder Neoplasms 29 Carcinoma, Non-Small-Cell Lung 21 Bile Duct Neoplasms 21 Locally Advanced Rectal Cancer 20 Adenocarcinoma Of Esophagus 20 Squamous Cell Carcinoma of Head and Neck 19 Brain Neoplasms 19 Gastrointestinal Neoplasms 18 Parkinson Disease 4, Autosomal Dominant Lewy Body 17 Liver Neoplasms 17 Head and Neck Neoplasms 17 Esophageal Squamous Cell Carcinoma 17 Colorectal Cancer Metastatic 15 Ovarian Neoplasms 14 Breast Neoplasms, Male 14

Interventions

toripalimab 1 camrelizumab 1 Radiotherapy 1 Nivolumab 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Tumors × Capecitabine × Clear all

NCT03781362 2022-07-20

Study of CPI-100 in Patients With Advanced Tumors

Coordination Pharmaceuticals, Inc.

Phase 1 Completed

Advanced Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡